Fmr LLC trimmed its position in shares of Selecta Biosciences Inc (NASDAQ:SELB) by 33.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 279,423 shares of the company’s stock after selling 139,556 shares during the quarter. Fmr LLC owned approximately 1.25% of Selecta Biosciences worth $3,702,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of SELB. BlackRock Inc. boosted its position in Selecta Biosciences by 40.4% during the 2nd quarter. BlackRock Inc. now owns 884,564 shares of the company’s stock valued at $11,721,000 after acquiring an additional 254,586 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Selecta Biosciences by 40.4% in the 1st quarter. JPMorgan Chase & Co. now owns 612,422 shares of the company’s stock worth $6,240,000 after purchasing an additional 176,111 shares in the last quarter. A.R.T. Advisors LLC boosted its position in shares of Selecta Biosciences by 225.5% in the 1st quarter. A.R.T. Advisors LLC now owns 59,584 shares of the company’s stock worth $607,000 after purchasing an additional 41,277 shares in the last quarter. Wasatch Advisors Inc. boosted its position in shares of Selecta Biosciences by 9.2% in the 2nd quarter. Wasatch Advisors Inc. now owns 235,625 shares of the company’s stock worth $3,122,000 after purchasing an additional 19,803 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Selecta Biosciences by 27.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,273 shares of the company’s stock worth $626,000 after purchasing an additional 10,114 shares in the last quarter. 48.74% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently commented on SELB shares. ValuEngine cut Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, June 26th. Janney Montgomery Scott started coverage on Selecta Biosciences in a research report on Wednesday, June 27th. They issued a “buy” rating and a $33.00 price target on the stock. Canaccord Genuity reissued a “buy” rating and issued a $40.00 price target on shares of Selecta Biosciences in a research report on Thursday, June 28th. BidaskClub cut Selecta Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 25th. Finally, Mizuho reissued a “buy” rating and issued a $30.00 price target on shares of Selecta Biosciences in a research report on Thursday, August 9th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $27.40.
Shares of SELB opened at $14.23 on Friday. The company has a current ratio of 4.96, a quick ratio of 4.96 and a debt-to-equity ratio of 0.87. Selecta Biosciences Inc has a 52 week low of $7.95 and a 52 week high of $24.02. The company has a market capitalization of $348.26 million, a PE ratio of -4.24 and a beta of -3.47.
Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings results on Wednesday, August 8th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). As a group, analysts forecast that Selecta Biosciences Inc will post -3.07 earnings per share for the current fiscal year.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Recommended Story: Moving Average – How it Helps Investors in Stock Selection
Want to see what other hedge funds are holding SELB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Selecta Biosciences Inc (NASDAQ:SELB).
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.